Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress [Yahoo! Finance]
Evaxion A/S - American Depositary Share (EVAX)
Company Research
Source: Yahoo! Finance
The AI-Immunology™ concepts include hybrid capsid designs and de novo designed B-cell antigen approaches Despite polio vaccines being available for decades, the highly infectious viral disease continues to pose a global health risk Evaxion will also present data from its EVX-V1 vaccine program targeting cytomegalovirus at the World Vaccine Congress COPENHAGEN, Denmark, March 30, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has in collaboration with the Gates Foundation developed novel and potentially superior concepts for design of vaccines to combat polio. These concepts, and the underlying research, will be presented at the World Vaccine Congress taking place in Washington D.C. from March 31 to April 2, 2026. Current polio vaccines are based on inactivated or attenuated versions of the virus. While these vaccines are effective, they each have shortcomings in certain set
Show less
Read more
Impact Snapshot
Event Time:
EVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVAX alerts
High impacting Evaxion A/S - American Depositary Share news events
Weekly update
A roundup of the hottest topics
EVAX
News
- Evaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial [Yahoo! Finance]Yahoo! Finance
- Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trialGlobeNewswire
- New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastomaGlobeNewswire
- Evaxion concludes Annual General MeetingGlobeNewswire
- Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01GlobeNewswire
EVAX
Sec Filings
- 4/17/26 - Form 6-K
- 4/17/26 - Form 6-K
- 4/16/26 - Form 6-K
- EVAX's page on the SEC website